Abstract 143P
Background
Patients with germline mutations in BRCA1/2 are at high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/2 mutations is still not a routine practice in the Middle East. With the lack of epidemiological studies in the region, we aim to describe the prevalence of BRCA1/2 mutations in patients with OC across different countries in the Gulf region.
Methods
The PREDICT study was an observational, prospective, epidemiological study on 105 women from three sites in the Gulf region; United Arab Emirates (UAE), Kuwait, and Oman. The prevalence of BRCA1/2 mutations in patients with ovarian, primary peritoneal, and fallopian tube cancer was determined by tissue genetic testing using next generation sequencing (NGS). Germline BRCA1/2 mutations, treatment patterns, and clinical characteristics of patients were also noted.
Results
The median age was 52 years (IQR 44.5 – 61.0) and 68.4% were Arab. The majority of patients had an ECOG performance status of 0 (65.7%) or 1 (24.8%). More than half of the patients (54.3 %) had advanced disease (FIGO stage III/IV) at presentation. Family history of OC or breast cancer was reported in 10 patients. A total of 99 (94.3%) patients received first-line chemotherapy, where 33.3% of them received chemotherapy as a neoadjuvant therapy, while 40 (38.1%) patients received second-line chemotherapy. Paclitaxel/carboplatin was the most frequently prescribed regimen, both as the first and the second-line treatment (79.8% and 32.5% of patients, respectively). 87 (82.9%) patients underwent debulking surgery, with no residual disease in 42.5%, optimal cytoreduction in 29.9%, and suboptimal cytoreduction in 25.3% of patients. Fifteen (17%) out of 88 patients were found to have mutations in either BRCA1, BRCA2, or both genes. Specifically, the prevalence of BRCA1/2 somatic mutations were 11.2% and 9.1%, respectively. 5 patients with BRCA1/2 somatic mutations had germline mutation tests and 3 of them tested positive.
Conclusions
The prevalence of BRCA1/2 mutations in patients with OC was comparable with global data. However, further evaluation of germline and somatic BRCA1/2 mutations is warranted to better understand their impact on OC patient outcomes in Gulf countries.
Clinical trial identification
NCT03082976.
Editorial acknowledgement
Mohamed Salman Head of Medical Affairs Company: Clinart MENA.
Legal entity responsible for the study
AstraZeneca FZ LLC - Gulf/GCC region.
Funding
AstraZeneca FZ LLC - Gulf/GCC region.
Disclosure
F. Azribi: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca, BMS, Pfizer, Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Amgen, MSD. I. Burney: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca. All other authors have declared no conflicts of interest.